Modality
mAb
MOA
WRNi
Target
CD47
Pathway
Fibrosis
LN
Development Pipeline
Preclinical
Sep 2020
→ Feb 2027
PreclinicalCurrent
NCT06039090
1,665 pts·LN
2020-09→2026-03·Not yet recruiting
NCT05932693
1,158 pts·LN
2025-02→2027-02·Recruiting
2,823 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-172w agoInterim· LN
2026-05-041mo awayBTD· LN
2027-02-2011mo awayInterim· LN
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2026-03-17 · 2w ago
LN
BTD
2026-05-04 · 1mo away
LN
Interim
2027-02-20 · 11mo away
LN
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06039090 | Preclinical | LN | Not yet recr... | 1665 | CR |
| NCT05932693 | Preclinical | LN | Recruiting | 1158 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 |